<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2018-03-26" updated="2019-12-02">
  <drugbank-id primary="true">DB14004</drugbank-id>
  <name>Tildrakizumab</name>
  <description>Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255].&#13;
&#13;
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter [L1858].&#13;
&#13;
A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257].</description>
  <cas-number>1326244-10-3</cas-number>
  <unii>DEW6X41BEK</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32248</ref-id>
        <pubmed-id>26042589</pubmed-id>
        <citation>Papp K, Thaci D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R: Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. doi: 10.1111/bjd.13932. Epub 2015 Oct 15.</citation>
      </article>
      <article>
        <ref-id>A32249</ref-id>
        <pubmed-id>28596043</pubmed-id>
        <citation>Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaci D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB: Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub  2017 Jun 6.</citation>
      </article>
      <article>
        <ref-id>A32255</ref-id>
        <pubmed-id>28271735</pubmed-id>
        <citation>Galluzzo M, D'adamio S, Bianchi L, Talamonti M: Tildrakizumab for treating psoriasis. Expert Opin Biol Ther. 2017 May;17(5):645-657. doi: 10.1080/14712598.2017.1304537. Epub 2017 Mar 17.</citation>
      </article>
      <article>
        <ref-id>A32256</ref-id>
        <pubmed-id>29510001</pubmed-id>
        <citation>Khalilieh S, Hodsman P, Xu C, Tzontcheva A, Glasgow S, Montgomery D: Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Subjects. Basic Clin Pharmacol Toxicol. 2018 Mar 6. doi: 10.1111/bcpt.13001.</citation>
      </article>
      <article>
        <ref-id>A32257</ref-id>
        <pubmed-id>25546162</pubmed-id>
        <citation>Zandvliet A, Glasgow S, Horowitz A, Montgomery D, Marjason J, Mehta A, Xu C, van Vugt M, Khalilieh S: Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects. Int J Clin Pharmacol Ther. 2015 Feb;53(2):139-46. doi: 10.5414/CP202176.</citation>
      </article>
      <article>
        <ref-id>A32258</ref-id>
        <pubmed-id>29271481</pubmed-id>
        <citation>Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1858</ref-id>
        <title>FDA Approves ILUMYA (tildrakizumab-asmn) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy</title>
        <url>http://s2027422842.t.en25.com/e/es?s=2027422842&amp;e=66767&amp;elqTrackId=78D8A052C380BCBFF284D754BEBE9730&amp;elq=096ab38d576c4c76b4f65be4cded361f&amp;elqaid=2935&amp;elqat=1</url>
      </link>
      <link>
        <ref-id>L1859</ref-id>
        <title>Ilumya</title>
        <url>https://www.psoriasis.org/content/ilumya-tildrakizumab-asmn</url>
      </link>
      <link>
        <ref-id>L1861</ref-id>
        <title>The safety and side effects of monoclonal antibodies</title>
        <url>http://theory.bio.uu.nl/immbio/pdf/TherapeuticReview2010.pdf</url>
      </link>
      <link>
        <ref-id>L1864</ref-id>
        <title>The effect of tildrakizumab, a high-affinity, selective anti-IL23p19 monoclonal antibody (mAb), on cytochrome P450 (CYP) metabolism</title>
        <url>http://www.jaad.org/article/S0190-9622(17)31465-2/fulltext</url>
      </link>
      <link>
        <ref-id>L1868</ref-id>
        <title>Tildrakizumab for treating psoriasis</title>
        <url>https://www.tandfonline.com/doi/abs/10.1080/14712598.2017.1304537?scroll=top&amp;needAccess=true&amp;journalCode=iebt20</url>
      </link>
      <link>
        <ref-id>L1869</ref-id>
        <title>Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value </title>
        <url>https://icer-review.org/wp-content/uploads/2017/11/ICER_Draft_Psoriasis_CU_Scope_120417.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Moderate-severe plaque psoriasis [L1858], [FDA label].</indication>
  <pharmacodynamics>Tildrakuzimab is a targeted immunomodulator that decreases inflammation by inhibiting the action of various cytokines associated with plaque psoriasis, thus relieving its symptom of scaly plaques [L1869], [FDA label].</pharmacodynamics>
  <mechanism-of-action>This drug selectively binds interleukin (IL)-23 p19 subunit of cytokine IL-23 and neutralizes its function IL-23 regulates Th17 cells and is a powerful activator of keratinocyte proliferation [A32256]. Targeting IL-23p19 alone has been found to be a promising treatment approach in patients with moderate-to-severe chronic plaque psoriasis.  Upon administration, downregulation of Th17 and Th22 cell responses occur [A32255].&#13;
&#13;
IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines [FDA label].</mechanism-of-action>
  <toxicity>It is advised to evaluate patients for tuberculosis infection prior to initiating treatment with ILUMYA.  This drug may increase the risk of infection [L1858]. It is advisable to perform tests for current tuberculosis status, as this drug may lead to reactivation of latent infection [FDA label].&#13;
&#13;
A common issue for monoclonal antibody drugs is the development of antibodies to the drugs, thus rendering them less effective or completely ineffective [L1861]. A clinical trial was done to assess antibody development to this drug [L1858], [FDA label]. Up until week 64, approximately 6.5% of subjects treated with ILUMYA 100 mg developed antibodies to tildrakizumab. Of the subjects who developed antibodies to tildrakizumab, approximately 40% (2.5% of all patients receiving ILUMYA) had antibodies that were considered neutralizing. The development of neutralizing antibodies to tildrakizumab was associated with lower serum tildrakizumab concentrations and decreased efficacy [FDA label].&#13;
&#13;
Most common (≥ 1% and at a higher rate than placebo) adverse reactions associated with ILUMYA treatment are upper respiratory infections, injection site reactions, and diarrhea [L1858].&#13;
&#13;
Cases of angioedema and urticaria occurred in ILUMYA treated subjects in various clinical trials. If a hypersensitivity reaction occurs, the drug should be discontinued immediately and appropriate therapy should be initiated [FDA label].&#13;
&#13;
In an embryo-fetal study, subcutaneous doses up to 300 mg/kg tildrakizumab were given to pregnant cynomolgus monkeys once every two weeks during organogenesis to 118 days gestation (22 days from parturition). No maternal or embryo-fetal toxicities were seen at doses up to 300 mg/kg (159 times the MRHD of 100 mg, based on AUC comparison). Tildrakizumab crossed the placenta in monkeys [FDA label].</toxicity>
  <metabolism>The metabolic pathway of tildrakizumab has not been characterized. As a humanized IgG1/k monoclonal antibody, tildrakizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG [L1858].&#13;
&#13;
The AUCinf of dextromethorphan (CYP2D6 substrate) increased by 20% when used concomitantly&#13;
with tildrakizumab 200 mg (two times the approved recommended dose) administered subcutaneously at Weeks 0 and 4 in subjects with plaque psoriasis. No clinically significant changes in AUCinf of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate) were observed [FDA label].</metabolism>
  <absorption>The mean (± SD) steady-state trough concentrations at 16 weeks post initiation of treatment ranged from 1.22 ± 0.94 mcg/mL to 1.47 ± 1.12 mcg/mL. The geometric mean (CV%) steady-state Cmax was 8.1 mcg/mL (34%) [L1858].&#13;
&#13;
The absolute bioavailability of tildrakizumab is estimated to be about 73-80% after subcutaneous administration. The peak concentration (Cmax) is reached by approximately 6 days [FDA label].</absorption>
  <half-life>The half-life is approximately 23 days (23%) [L1858].</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>The geometric mean (CV%) volume of distribution is 10.8 L (24%) [L1858].</volume-of-distribution>
  <clearance>The mean (CV%) systemic clearance is 0.32 L/day (38%) [L1858].</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">tildrakizumab-asmn</synonym>
  </synonyms>
  <products>
    <product>
      <name>Ilumya</name>
      <labeller>Sun Pharmaceutical Industries, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>47335-177</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA761067</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Ilumya</name>
      <ingredients>Tildrakizumab</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Interleukin Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Interleukin-23 Antagonist</category>
      <mesh-id/>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L04AC17">
      <level code="L04AC">Interleukin inhibitors</level>
      <level code="L04A">IMMUNOSUPPRESSANTS</level>
      <level code="L04">IMMUNOSUPPRESSANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB14004.pdf?1522087237</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>Chlorotrianisene may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00890</drugbank-id>
      <name>Dienestrol</name>
      <description>Dienestrol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>Mestranol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Estrone sulfate may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>Hexestrol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Esterified estrogens</name>
      <description>Esterified estrogens may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>Equol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>Methallenestril may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13386</drugbank-id>
      <name>Epimestrol</name>
      <description>Epimestrol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13418</drugbank-id>
      <name>Moxestrol</name>
      <description>Moxestrol may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15334</drugbank-id>
      <name>Biochanin A</name>
      <description>Biochanin A may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15335</drugbank-id>
      <name>Formononetin</name>
      <description>Formononetin may increase the thrombogenic activities of Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00002</drugbank-id>
      <name>Cetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Cetuximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00028</drugbank-id>
      <name>Human immunoglobulin G</name>
      <description>The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00043</drugbank-id>
      <name>Omalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Omalizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of adverse effects can be increased when Abciximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00057</drugbank-id>
      <name>Indium In-111 satumomab pendetide</name>
      <description>The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00076</drugbank-id>
      <name>Digoxin Immune Fab (Ovine)</name>
      <description>The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00089</drugbank-id>
      <name>Capromab pendetide</name>
      <description>The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00110</drugbank-id>
      <name>Palivizumab</name>
      <description>The risk or severity of adverse effects can be increased when Palivizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00113</drugbank-id>
      <name>Technetium Tc-99m arcitumomab</name>
      <description>The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01269</drugbank-id>
      <name>Panitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Panitumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01270</drugbank-id>
      <name>Ranibizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04901</drugbank-id>
      <name>Galiximab</name>
      <description>The risk or severity of adverse effects can be increased when Galiximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04949</drugbank-id>
      <name>Pexelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Pexelizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04958</drugbank-id>
      <name>Epratuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Epratuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04962</drugbank-id>
      <name>Bectumomab</name>
      <description>The risk or severity of adverse effects can be increased when Bectumomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04964</drugbank-id>
      <name>Oregovomab</name>
      <description>The risk or severity of adverse effects can be increased when Oregovomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04988</drugbank-id>
      <name>IGN311</name>
      <description>The risk or severity of adverse effects can be increased when IGN311 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05006</drugbank-id>
      <name>Adecatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05097</drugbank-id>
      <name>Labetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Labetuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05101</drugbank-id>
      <name>Matuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Matuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05111</drugbank-id>
      <name>Fontolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fontolizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05136</drugbank-id>
      <name>Bavituximab</name>
      <description>The risk or severity of adverse effects can be increased when Bavituximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05139</drugbank-id>
      <name>CR002</name>
      <description>The risk or severity of adverse effects can be increased when CR002 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05209</drugbank-id>
      <name>Rozrolimupab</name>
      <description>The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05304</drugbank-id>
      <name>Girentuximab</name>
      <description>The risk or severity of adverse effects can be increased when Girentuximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05336</drugbank-id>
      <name>Obiltoxaximab</name>
      <description>The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05405</drugbank-id>
      <name>XTL-001</name>
      <description>The risk or severity of adverse effects can be increased when XTL-001 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05437</drugbank-id>
      <name>NAV 1800</name>
      <description>The risk or severity of adverse effects can be increased when NAV 1800 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05496</drugbank-id>
      <name>Otelixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Otelixizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05545</drugbank-id>
      <name>AMG 108</name>
      <description>The risk or severity of adverse effects can be increased when AMG 108 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05550</drugbank-id>
      <name>Iratumumab</name>
      <description>The risk or severity of adverse effects can be increased when Iratumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05555</drugbank-id>
      <name>Enokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Enokizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05578</drugbank-id>
      <name>Ramucirumab</name>
      <description>The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05595</drugbank-id>
      <name>Farletuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Farletuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05656</drugbank-id>
      <name>Veltuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Veltuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05793</drugbank-id>
      <name>PRO-542</name>
      <description>The risk or severity of adverse effects can be increased when PRO-542 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05797</drugbank-id>
      <name>TNX-901</name>
      <description>The risk or severity of adverse effects can be increased when TNX-901 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05892</drugbank-id>
      <name>RI 624</name>
      <description>The risk or severity of adverse effects can be increased when RI 624 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05915</drugbank-id>
      <name>MYO-029</name>
      <description>The risk or severity of adverse effects can be increased when MYO-029 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05916</drugbank-id>
      <name>CT-011</name>
      <description>The risk or severity of adverse effects can be increased when CT-011 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05941</drugbank-id>
      <name>Leronlimab</name>
      <description>The risk or severity of adverse effects can be increased when Leronlimab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05996</drugbank-id>
      <name>Glembatumumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06043</drugbank-id>
      <name>Olaratumab</name>
      <description>The risk or severity of adverse effects can be increased when Olaratumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06049</drugbank-id>
      <name>IPH 2101</name>
      <description>The risk or severity of adverse effects can be increased when IPH 2101 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06050</drugbank-id>
      <name>TB-402</name>
      <description>The risk or severity of adverse effects can be increased when TB-402 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06101</drugbank-id>
      <name>IMC-1C11</name>
      <description>The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06116</drugbank-id>
      <name>Eldelumab</name>
      <description>The risk or severity of adverse effects can be increased when Eldelumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06162</drugbank-id>
      <name>Lumiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Lumiliximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06192</drugbank-id>
      <name>Nimotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06241</drugbank-id>
      <name>Clenoliximab</name>
      <description>The risk or severity of adverse effects can be increased when Clenoliximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06304</drugbank-id>
      <name>BIIB015</name>
      <description>The risk or severity of adverse effects can be increased when BIIB015 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06305</drugbank-id>
      <name>Sonepcizumab</name>
      <description>The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06310</drugbank-id>
      <name>Motavizumab</name>
      <description>The risk or severity of adverse effects can be increased when Motavizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06317</drugbank-id>
      <name>Elotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Elotuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06318</drugbank-id>
      <name>AVE9633</name>
      <description>The risk or severity of adverse effects can be increased when AVE9633 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06322</drugbank-id>
      <name>Carotuximab</name>
      <description>The risk or severity of adverse effects can be increased when Carotuximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06324</drugbank-id>
      <name>XmAb 2513</name>
      <description>The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06342</drugbank-id>
      <name>Coltuximab ravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06343</drugbank-id>
      <name>Teprotumumab</name>
      <description>The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06360</drugbank-id>
      <name>Lucatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Lucatumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06366</drugbank-id>
      <name>Pertuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Pertuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06371</drugbank-id>
      <name>Siplizumab</name>
      <description>The risk or severity of adverse effects can be increased when Siplizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06467</drugbank-id>
      <name>Apolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Apolizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06474</drugbank-id>
      <name>Sibrotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06550</drugbank-id>
      <name>Bivatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06557</drugbank-id>
      <name>Lerdelimumab</name>
      <description>The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06599</drugbank-id>
      <name>Lexatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Lexatumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06602</drugbank-id>
      <name>Reslizumab</name>
      <description>The risk or severity of adverse effects can be increased when Reslizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06606</drugbank-id>
      <name>Teplizumab</name>
      <description>The risk or severity of adverse effects can be increased when Teplizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06607</drugbank-id>
      <name>Catumaxomab</name>
      <description>The risk or severity of adverse effects can be increased when Catumaxomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06647</drugbank-id>
      <name>Volociximab</name>
      <description>The risk or severity of adverse effects can be increased when Volociximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06650</drugbank-id>
      <name>Ofatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Ofatumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08902</drugbank-id>
      <name>Raxibacumab</name>
      <description>The risk or severity of adverse effects can be increased when Raxibacumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09035</drugbank-id>
      <name>Nivolumab</name>
      <description>The risk or severity of adverse effects can be increased when Nivolumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09037</drugbank-id>
      <name>Pembrolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The risk or severity of adverse effects can be increased when Dulaglutide is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09105</drugbank-id>
      <name>Asfotase alfa</name>
      <description>The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Idarucizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09302</drugbank-id>
      <name>Alirocumab</name>
      <description>The risk or severity of adverse effects can be increased when Alirocumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09303</drugbank-id>
      <name>Evolocumab</name>
      <description>The risk or severity of adverse effects can be increased when Evolocumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09331</drugbank-id>
      <name>Daratumumab</name>
      <description>The risk or severity of adverse effects can be increased when Daratumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09559</drugbank-id>
      <name>Necitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Necitumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11595</drugbank-id>
      <name>Atezolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Atezolizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11604</drugbank-id>
      <name>Tetanus Immune Globulin</name>
      <description>The risk or severity of adverse effects can be increased when Tetanus Immune Globulin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11621</drugbank-id>
      <name>Human Varicella-Zoster Immune Globulin</name>
      <description>The risk or severity of adverse effects can be increased when Human Varicella-Zoster Immune Globulin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11646</drugbank-id>
      <name>Conatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Conatumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11657</drugbank-id>
      <name>Tabalumab</name>
      <description>The risk or severity of adverse effects can be increased when Tabalumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11680</drugbank-id>
      <name>Ficlatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11685</drugbank-id>
      <name>Figitumumab</name>
      <description>The risk or severity of adverse effects can be increased when Figitumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11714</drugbank-id>
      <name>Durvalumab</name>
      <description>The risk or severity of adverse effects can be increased when Durvalumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11715</drugbank-id>
      <name>Bapineuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Bapineuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11731</drugbank-id>
      <name>Depatuxizumab mafodotin</name>
      <description>The risk or severity of adverse effects can be increased when Depatuxizumab mafodotin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11746</drugbank-id>
      <name>Onartuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Onartuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11756</drugbank-id>
      <name>Solanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Solanezumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11771</drugbank-id>
      <name>Tremelimumab</name>
      <description>The risk or severity of adverse effects can be increased when Tremelimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11826</drugbank-id>
      <name>Lampalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Lampalizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11840</drugbank-id>
      <name>Dalotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Dalotuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11849</drugbank-id>
      <name>Emibetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Emibetuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11850</drugbank-id>
      <name>Ublituximab</name>
      <description>The risk or severity of adverse effects can be increased when Ublituximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11856</drugbank-id>
      <name>Ligelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ligelizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11857</drugbank-id>
      <name>Seribantumab</name>
      <description>The risk or severity of adverse effects can be increased when Seribantumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11862</drugbank-id>
      <name>Landogrozumab</name>
      <description>The risk or severity of adverse effects can be increased when Landogrozumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11866</drugbank-id>
      <name>Romosozumab</name>
      <description>The risk or severity of adverse effects can be increased when Romosozumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11884</drugbank-id>
      <name>Vadastuximab Talirine</name>
      <description>The risk or severity of adverse effects can be increased when Vadastuximab Talirine is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11914</drugbank-id>
      <name>Lebrikizumab</name>
      <description>The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11930</drugbank-id>
      <name>Varlilumab</name>
      <description>The risk or severity of adverse effects can be increased when Varlilumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11945</drugbank-id>
      <name>Avelumab</name>
      <description>The risk or severity of adverse effects can be increased when Avelumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11959</drugbank-id>
      <name>Crenezumab</name>
      <description>The risk or severity of adverse effects can be increased when Crenezumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11972</drugbank-id>
      <name>Rilotumumab</name>
      <description>The risk or severity of adverse effects can be increased when Rilotumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11976</drugbank-id>
      <name>Anifrolumab</name>
      <description>The risk or severity of adverse effects can be increased when Anifrolumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12023</drugbank-id>
      <name>Benralizumab</name>
      <description>The risk or severity of adverse effects can be increased when Benralizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12034</drugbank-id>
      <name>Gantenerumab</name>
      <description>The risk or severity of adverse effects can be increased when Gantenerumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12053</drugbank-id>
      <name>Visilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Visilizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12077</drugbank-id>
      <name>Urelumab</name>
      <description>The risk or severity of adverse effects can be increased when Urelumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12090</drugbank-id>
      <name>Patritumab</name>
      <description>The risk or severity of adverse effects can be increased when Patritumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12102</drugbank-id>
      <name>Fulranumab</name>
      <description>The risk or severity of adverse effects can be increased when Fulranumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12104</drugbank-id>
      <name>Tarextumab</name>
      <description>The risk or severity of adverse effects can be increased when Tarextumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12118</drugbank-id>
      <name>Sotatercept</name>
      <description>The risk or severity of adverse effects can be increased when Sotatercept is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12119</drugbank-id>
      <name>Gevokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Gevokizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12142</drugbank-id>
      <name>Duligotuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Duligotuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12152</drugbank-id>
      <name>Simtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Simtuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12157</drugbank-id>
      <name>Fasinumab</name>
      <description>The risk or severity of adverse effects can be increased when Fasinumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12159</drugbank-id>
      <name>Dupilumab</name>
      <description>The risk or severity of adverse effects can be increased when Dupilumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12169</drugbank-id>
      <name>Tralokinumab</name>
      <description>The risk or severity of adverse effects can be increased when Tralokinumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12189</drugbank-id>
      <name>Etrolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Etrolizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12202</drugbank-id>
      <name>Zalutumumab</name>
      <description>The risk or severity of adverse effects can be increased when Zalutumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12205</drugbank-id>
      <name>Ganitumab</name>
      <description>The risk or severity of adverse effects can be increased when Ganitumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12213</drugbank-id>
      <name>Etaracizumab</name>
      <description>The risk or severity of adverse effects can be increased when Etaracizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12240</drugbank-id>
      <name>Polatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12246</drugbank-id>
      <name>Inclacumab</name>
      <description>The risk or severity of adverse effects can be increased when Inclacumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12250</drugbank-id>
      <name>Cixutumumab</name>
      <description>The risk or severity of adverse effects can be increased when Cixutumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12261</drugbank-id>
      <name>Ascrinvacumab</name>
      <description>The risk or severity of adverse effects can be increased when Ascrinvacumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12274</drugbank-id>
      <name>Aducanumab</name>
      <description>The risk or severity of adverse effects can be increased when Aducanumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12281</drugbank-id>
      <name>Luspatercept</name>
      <description>The risk or severity of adverse effects can be increased when Luspatercept is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12296</drugbank-id>
      <name>GS-5745</name>
      <description>The risk or severity of adverse effects can be increased when GS-5745 is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12317</drugbank-id>
      <name>Vanucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Vanucizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12331</drugbank-id>
      <name>Labetuzumab govitecan</name>
      <description>The risk or severity of adverse effects can be increased when Labetuzumab govitecan is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12335</drugbank-id>
      <name>Tanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Tanezumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12342</drugbank-id>
      <name>Ensituximab</name>
      <description>The risk or severity of adverse effects can be increased when Ensituximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12344</drugbank-id>
      <name>Fezakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Fezakinumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12363</drugbank-id>
      <name>Dusigitumab</name>
      <description>The risk or severity of adverse effects can be increased when Dusigitumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12396</drugbank-id>
      <name>Fresolimumab</name>
      <description>The risk or severity of adverse effects can be increased when Fresolimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12413</drugbank-id>
      <name>Indusatumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Indusatumab vedotin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12456</drugbank-id>
      <name>Bococizumab</name>
      <description>The risk or severity of adverse effects can be increased when Bococizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12489</drugbank-id>
      <name>Mirvetuximab Soravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12498</drugbank-id>
      <name>Mogamulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12520</drugbank-id>
      <name>Plozalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Plozalizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12530</drugbank-id>
      <name>Inebilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Inebilizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12534</drugbank-id>
      <name>Mavrilimumab</name>
      <description>The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12560</drugbank-id>
      <name>Blosozumab</name>
      <description>The risk or severity of adverse effects can be increased when Blosozumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12584</drugbank-id>
      <name>Bimagrumab</name>
      <description>The risk or severity of adverse effects can be increased when Bimagrumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12589</drugbank-id>
      <name>Dacetuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12609</drugbank-id>
      <name>Tovetumab</name>
      <description>The risk or severity of adverse effects can be increased when Tovetumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12683</drugbank-id>
      <name>Lumretuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Lumretuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12698</drugbank-id>
      <name>Ibalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ibalizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12701</drugbank-id>
      <name>Intetumumab</name>
      <description>The risk or severity of adverse effects can be increased when Intetumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12718</drugbank-id>
      <name>Carlumab</name>
      <description>The risk or severity of adverse effects can be increased when Carlumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12734</drugbank-id>
      <name>Demcizumab</name>
      <description>The risk or severity of adverse effects can be increased when Demcizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12773</drugbank-id>
      <name>Sifalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Sifalimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12775</drugbank-id>
      <name>Abituzumab</name>
      <description>The risk or severity of adverse effects can be increased when Abituzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12797</drugbank-id>
      <name>Ecromeximab</name>
      <description>The risk or severity of adverse effects can be increased when Ecromeximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12807</drugbank-id>
      <name>Naptumomab Estafenatox</name>
      <description>The risk or severity of adverse effects can be increased when Naptumomab Estafenatox is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12815</drugbank-id>
      <name>Crotedumab</name>
      <description>The risk or severity of adverse effects can be increased when Crotedumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12820</drugbank-id>
      <name>Concizumab</name>
      <description>The risk or severity of adverse effects can be increased when Concizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12826</drugbank-id>
      <name>Depatuxizumab</name>
      <description>The risk or severity of adverse effects can be increased when Depatuxizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12844</drugbank-id>
      <name>Rontalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Rontalizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12845</drugbank-id>
      <name>Amatuximab</name>
      <description>The risk or severity of adverse effects can be increased when Amatuximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12849</drugbank-id>
      <name>Clazakizumab</name>
      <description>The risk or severity of adverse effects can be increased when Clazakizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12891</drugbank-id>
      <name>Ozanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Ozanezumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12893</drugbank-id>
      <name>Sacituzumab govitecan</name>
      <description>The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12917</drugbank-id>
      <name>Bimekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Bimekizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12943</drugbank-id>
      <name>Milatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Milatuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12976</drugbank-id>
      <name>Robatumumab</name>
      <description>The risk or severity of adverse effects can be increased when Robatumumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13017</drugbank-id>
      <name>Rovalpituzumab Tesirine</name>
      <description>The risk or severity of adverse effects can be increased when Rovalpituzumab Tesirine is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13037</drugbank-id>
      <name>Namilumab</name>
      <description>The risk or severity of adverse effects can be increased when Namilumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13045</drugbank-id>
      <name>Racotumomab</name>
      <description>The risk or severity of adverse effects can be increased when Racotumomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13073</drugbank-id>
      <name>Tregalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tregalizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13127</drugbank-id>
      <name>Olokizumab</name>
      <description>The risk or severity of adverse effects can be increased when Olokizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13140</drugbank-id>
      <name>Bezlotoxumab</name>
      <description>The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13375</drugbank-id>
      <name>Edrecolomab</name>
      <description>The risk or severity of adverse effects can be increased when Edrecolomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13535</drugbank-id>
      <name>Nebacumab</name>
      <description>The risk or severity of adverse effects can be increased when Nebacumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13886</drugbank-id>
      <name>Human cytomegalovirus immune globulin</name>
      <description>The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>The risk or severity of adverse effects can be increased when Emicizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13976</drugbank-id>
      <name>Sulesomab</name>
      <description>The risk or severity of adverse effects can be increased when Sulesomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13979</drugbank-id>
      <name>Besilesomab</name>
      <description>The risk or severity of adverse effects can be increased when Besilesomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14012</drugbank-id>
      <name>Burosumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Burosumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14039</drugbank-id>
      <name>Erenumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Erenumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14040</drugbank-id>
      <name>Eptinezumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Eptinezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14041</drugbank-id>
      <name>Fremanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Fremanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14042</drugbank-id>
      <name>Galcanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Galcanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14211</drugbank-id>
      <name>Fanolesomab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Fanolesomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14580</drugbank-id>
      <name>BAN-2401</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with BAN-2401.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14597</drugbank-id>
      <name>Lanadelumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Lanadelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14707</drugbank-id>
      <name>Cemiplimab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Cemiplimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14776</drugbank-id>
      <name>Camrelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Camrelizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14778</drugbank-id>
      <name>Setrusumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Setrusumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14784</drugbank-id>
      <name>Gancotamab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Gancotamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14809</drugbank-id>
      <name>Anetumab ravtansine</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Anetumab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14811</drugbank-id>
      <name>Isatuximab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Isatuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14824</drugbank-id>
      <name>Icrucumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Icrucumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14843</drugbank-id>
      <name>Codrituzumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Codrituzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14864</drugbank-id>
      <name>Brolucizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Brolucizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14871</drugbank-id>
      <name>Xentuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Xentuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14877</drugbank-id>
      <name>Lintuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Lintuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14891</drugbank-id>
      <name>Vobarilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Vobarilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14897</drugbank-id>
      <name>Parsatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Parsatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14905</drugbank-id>
      <name>Emactuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Emactuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14907</drugbank-id>
      <name>Bevacizumab zirconium Zr-89</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Bevacizumab zirconium Zr-89.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14908</drugbank-id>
      <name>Refanezumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Refanezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14947</drugbank-id>
      <name>Bermekimab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Bermekimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14952</drugbank-id>
      <name>Pamrevlumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Pamrevlumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14959</drugbank-id>
      <name>Opicinumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Opicinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Trastuzumab deruxtecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14967</drugbank-id>
      <name>Margetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Margetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14988</drugbank-id>
      <name>Dalantercept</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Dalantercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14997</drugbank-id>
      <name>Pateclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Pateclizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15014</drugbank-id>
      <name>Gremubamab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Gremubamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15022</drugbank-id>
      <name>Apomab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Apomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15044</drugbank-id>
      <name>Tafasitamab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Tafasitamab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15045</drugbank-id>
      <name>Ipafricept</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Ipafricept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15076</drugbank-id>
      <name>Abrilumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Abrilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15089</drugbank-id>
      <name>Frovocimab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Frovocimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15090</drugbank-id>
      <name>Tezepelumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Tezepelumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15101</drugbank-id>
      <name>Tigatuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Tigatuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15104</drugbank-id>
      <name>Telisotuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Telisotuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15113</drugbank-id>
      <name>Utomilumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Utomilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15118</drugbank-id>
      <name>Zolbetuximab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Zolbetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15135</drugbank-id>
      <name>Ponezumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Ponezumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15160</drugbank-id>
      <name>Asunercept</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Asunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15172</drugbank-id>
      <name>Suvratoxumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Suvratoxumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15225</drugbank-id>
      <name>Mitazalimab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Mitazalimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15252</drugbank-id>
      <name>Nemolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Nemolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15277</drugbank-id>
      <name>Gedivumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Gedivumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15336</drugbank-id>
      <name>Valanafusp alfa</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Valanafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15349</drugbank-id>
      <name>Sofituzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Sofituzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15354</drugbank-id>
      <name>Evinacumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Evinacumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15363</drugbank-id>
      <name>Istiratumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Istiratumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15383</drugbank-id>
      <name>Pidilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Pidilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15397</drugbank-id>
      <name>GMA-161</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with GMA-161.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15409</drugbank-id>
      <name>Ladiratuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Ladiratuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15415</drugbank-id>
      <name>Tomaralimab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Tomaralimab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15428</drugbank-id>
      <name>Vesencumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Vesencumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15432</drugbank-id>
      <name>Pinatuzumab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Pinatuzumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15441</drugbank-id>
      <name>Lulizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Lulizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15443</drugbank-id>
      <name>Lorukafusp alfa</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Lorukafusp alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15453</drugbank-id>
      <name>Naratuximab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Naratuximab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Adalimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The risk or severity of adverse effects can be increased when Infliximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Rituximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Basiliximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The risk or severity of adverse effects can be increased when Muromonab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Tositumomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Efalizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Natalizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Daclizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The risk or severity of adverse effects can be increased when Eculizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The risk or severity of adverse effects can be increased when Afelimomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Briakinumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05679</drugbank-id>
      <name>Ustekinumab</name>
      <description>The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Canakinumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tocilizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Mepolizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Denosumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The risk or severity of adverse effects can be increased when Golimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Belimumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The risk or severity of adverse effects can be increased when Secukinumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Vedolizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The risk or severity of adverse effects can be increased when Siltuximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Dinutuximab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ixekizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ravulizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The risk or severity of adverse effects can be increased when Sarilumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The risk or severity of adverse effects can be increased when Brodalumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The risk or severity of adverse effects can be increased when Sirukumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The risk or severity of adverse effects can be increased when Guselkumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Tildrakizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15559</drugbank-id>
      <name>Zenocutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Zenocutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15595</drugbank-id>
      <name>Ebola Zaire vaccine (live, attenuated)</name>
      <description>The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Tildrakizumab.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Tildrakizumab Sequence
MLGSRAVMLLLLLPWTAQGRAVPGGSSPAWTQCQQLSQKLCTLAWSAHPLVGHMDLREEG
DEETTNDVPHIQCGDGCDPQGLRDNSQFCLQRIHQGLIFYEKLLGSDIFTGEPSLLPDSP
VGQLHASLLGLSQLLQPEGHHWETQQIPSLSPSQPWQRLLLRFKILRSLQAFVAVAARVF
AHGAATLSP</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>144400.0</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6426H9918N1698O2000S46</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D10400</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tildrakizumab</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0008663</id>
      <name>Interleukin-23</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32248</ref-id>
            <pubmed-id>26042589</pubmed-id>
            <citation>Papp K, Thaci D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R: Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. doi: 10.1111/bjd.13932. Epub 2015 Oct 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1859</ref-id>
            <title>Ilumya</title>
            <url>https://www.psoriasis.org/content/ilumya-tildrakizumab-asmn</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P29460" source="Swiss-Prot">
        <name>Interleukin-12 subunit beta</name>
        <general-function>Protein heterodimerization activity</general-function>
        <specific-function>Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.Associates with IL23A to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.</specific-function>
        <gene-name>IL12B</gene-name>
        <locus>5q31.1-q33.1</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>5.47</theoretical-pi>
        <molecular-weight>37168.645</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IL12B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M65272</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>180626</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29460</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IL12B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CLMF p40</synonym>
          <synonym>Cytotoxic lymphocyte maturation factor 40 kDa subunit</synonym>
          <synonym>IL-12 subunit p40</synonym>
          <synonym>IL-12B</synonym>
          <synonym>NK cell stimulatory factor chain 2</synonym>
          <synonym>NKSF2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016273|Interleukin-12 subunit beta
MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITW
TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ
KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV
RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKN
LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVIC
RKNASISVRAQDRYYSSSWSEWASVPCS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016274|Interleukin-12 subunit beta (IL12B)
ATGTGTCACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGTTTTTCTGGCATCTCCCCTC
GTGGCCATATGGGAACTGAAGAAAGATGTTTATGTCGTAGAATTGGATTGGTATCCGGAT
GCCCCTGGAGAAATGGTGGTCCTCACCTGTGACACCCCTGAAGAAGATGGTATCACCTGG
ACCTTGGACCAGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCCTGACCATCCAAGTCAAA
GAGTTTGGAGATGCTGGCCAGTACACCTGTCACAAAGGAGGCGAGGTTCTAAGCCATTCG
CTCCTGCTGCTTCACAAAAAGGAAGATGGAATTTGGTCCACTGATATTTTAAAGGACCAG
AAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGGCCAAGAATTATTCTGGACGTTTC
ACCTGCTGGTGGCTGACGACAATCAGTACTGATTTGACATTCAGTGTCAAAAGCAGCAGA
GGCTCTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCTACACTCTCTGCAGAGAGAGTC
AGAGGGGACAACAAGGAGTATGAGTACTCAGTGGAGTGCCAGGAGGACAGTGCCTGCCCA
GCTGCTGAGGAGAGTCTGCCCATTGAGGTCATGGTGGATGCCGTTCACAAGCTCAAGTAT
GAAAACTACACCAGCAGCTTCTTCATCAGGGACATCATCAAACCTGACCCACCCAAGAAC
TTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTGAC
ACCTGGAGTACTCCACATTCCTACTTCTCCCTGACATTCTGCGTTCAGGTCCAGGGCAAG
AGCAAGAGAGAAAAGAAAGATAGAGTCTTCACGGACAAGACCTCAGCCACGGTCATCTGC
CGCAAAAATGCCAGCATTAGCGTGCGGGCCCAGGACCGCTACTATAGCTCATCTTGGAGC
GAATGGGCATCTGTGCCCTGCAGTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF10420</identifier>
            <name>IL12p40_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>interleukin-12 complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>interleukin-23 complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cytokine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>interleukin-12 alpha subunit binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>interleukin-12 receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle arrest</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to interferon-gamma</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to Gram-negative bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to protozoan</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interferon-gamma biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>natural killer cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>natural killer cell activation involved in immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of growth of symbiont in host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of inflammatory response to antigenic stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-10 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-17 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of activated T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of activation of JAK2 kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of defense response to virus by host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of granulocyte macrophage colony-stimulating factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-10 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-12 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-17 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of lymphocyte proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of memory T cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mononuclear cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of natural killer cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of natural killer cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NK T cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NK T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of osteoclast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle cell apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T cell mediated cytotoxicity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T-helper 1 type immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T-helper 17 cell lineage commitment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T-helper 17 type immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tissue remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tyrosine phosphorylation of Stat3 protein</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tyrosine phosphorylation of Stat4 protein</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tyrosine phosphorylation of Stat5 protein</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cytokine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of tyrosine phosphorylation of Stat1 protein</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to UV-B</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sexual reproduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T-helper 1 type immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T-helper cell differentiation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9NPF7" source="Swiss-Prot">
        <name>Interleukin-23 subunit alpha</name>
        <general-function/>
        <specific-function>Associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.</specific-function>
        <gene-name>IL23A</gene-name>
        <locus>12q13.2</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>6.5</theoretical-pi>
        <molecular-weight>20729.56</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:15488</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IL23A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF301620</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NPF7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IL23A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>IL-23 subunit alpha</synonym>
          <synonym>IL-23p19</synonym>
          <synonym>Interleukin-23 subunit p19</synonym>
          <synonym>SGRF</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020688|Interleukin-23 subunit alpha
MLGSRAVMLLLLLPWTAQGRAVPGGSSPAWTQCQQLSQKLCTLAWSAHPLVGHMDLREEG
DEETTNDVPHIQCGDGCDPQGLRDNSQFCLQRIHQGLIFYEKLLGSDIFTGEPSLLPDSP
VGQLHASLLGLSQLLQPEGHHWETQQIPSLSPSQPWQRLLLRFKILRSLQAFVAVAARVF
AHGAATLSP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020689|Interleukin-23 subunit alpha (IL23A)
ATGCTGGGGAGCAGAGCTGTAATGCTGCTGTTGCTGCTGCCCTGGACAGCTCAGGGCAGA
GCTGTGCCTGGGGGCAGCAGCCCTGCCTGGACTCAGTGCCAGCAGCTTTCACAGAAGCTC
TGCACACTGGCCTGGAGTGCACATCCACTAGTGGGACACATGGATCTAAGAGAAGAGGGA
GATGAAGAGACTACAAATGATGTTCCCCATATCCAGTGTGGAGATGGCTGTGACCCCCAA
GGACTCAGGGACAACAGTCAGTTCTGCTTGCAAAGGATCCACCAGGGTCTGATTTTTTAT
GAGAAGCTGCTAGGATCGGATATTTTCACAGGGGAGCCTTCTCTGCTCCCTGATAGCCCT
GTGGGCCAGCTTCATGCCTCCCTACTGGGCCTCAGCCAACTCCTGCAGCCTGAGGGTCAC
CACTGGGAGACTCAGCAGATTCCAAGCCTCAGTCCCAGCCAGCCATGGCAGCGTCTCCTT
CTCCGCTTCAAAATCCTTCGCAGCCTCCAGGCCTTTGTGGCTGTAGCCGCCCGGGTCTTT
GCCCATGGAGCAGCAACCCTGAGTCCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF16649</identifier>
            <name>IL23</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>interleukin-23 complex</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to Gram-negative bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-10 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of activated T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of activation of JAK2 kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of defense response to virus by host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of granulocyte macrophage colony-stimulating factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-10 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-12 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-17 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of memory T cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of natural killer cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of natural killer cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NK T cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NK T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of osteoclast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T cell mediated cytotoxicity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T-helper 1 type immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T-helper 17 cell lineage commitment</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of T-helper 17 type immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tissue remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tyrosine phosphorylation of Stat3 protein</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tyrosine phosphorylation of Stat4 protein</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tyrosine phosphorylation of Stat5 protein</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of tyrosine phosphorylation of Stat1 protein</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tissue remodeling</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="2">
      <id>BE0000421</id>
      <name>Cytochrome P450 4A11</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q02928" source="Swiss-Prot">
        <name>Cytochrome P450 4A11</name>
        <general-function>Leukotriene-b4 20-monooxygenase activity</general-function>
        <specific-function>Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).</specific-function>
        <gene-name>CYP4A11</gene-name>
        <locus>1p33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.99</theoretical-pi>
        <molecular-weight>59347.31</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2642</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP4A11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L04751</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q02928</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP4AB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>20-HETE synthase</synonym>
          <synonym>20-hydroxyeicosatetraenoic acid synthase</synonym>
          <synonym>CYP4A2</synonym>
          <synonym>CYP4AII</synonym>
          <synonym>CYPIVA11</synonym>
          <synonym>Cytochrome P-450HK-omega</synonym>
          <synonym>Cytochrome P450HL-omega</synonym>
          <synonym>Fatty acid omega-hydroxylase</synonym>
          <synonym>Lauric acid omega-hydroxylase</synonym>
          <synonym>Long-chain fatty acid omega-monooxygenase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000839|Cytochrome P450 4A11
MSVSVLSPSRLLGDVSGILQAASLLILLLLLIKAVQLYLHRQWLLKALQQFPCPPSHWLF
GHIQELQQDQELQRIQKWVETFPSACPHWLWGGKVRVQLYDPDYMKVILGRSDPKSHGSY
RFLAPWIGYGLLLLNGQTWFQHRRMLTPAFHYDILKPYVGLMADSVRVMLDKWEELLGQD
SPLEVFQHVSLMTLDTIMKCAFSHQGSIQVDRNSQSYIQAISDLNNLVFSRVRNAFHQND
TIYSLTSAGRWTHRACQLAHQHTDQVIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKM
ENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHSLLGDGAS
ITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTFPDGRSLPKGIMVLLSIYGLHH
NPKVWPNPEVFDPFRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNELKVATALTLLRFEL
LPDPTRIPIPIARLVLKSKNGIHLRLRRLPNPCEDKDQL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020457|Cytochrome P450 4A11 (CYP4A11)
ATGAGTGTCTCTGTGCTGAGCCCCAGCAGACTCCTGGGTGATGTCTCTGGAATCCTCCAA
GCGGCCTCCCTGCTCATTCTGCTTCTGCTGCTGATCAAGGCAGTTCAGCTCTACCTGCAC
AGGCAGTGGCTGCTCAAAGCCCTCCAGCAGTTCCCGTGCCCTCCCTCCCACTGGCTCTTC
GGGCACATCCAGGAGCTCCAACAGGACCAGGAGCTACAACGGATTCAGAAATGGGTGGAG
ACATTCCCAAGTGCCTGTCCTCATTGGCTATGGGGAGGCAAAGTTCGTGTCCAGCTCTAT
GACCCTGACTATATGAAGGTGATTCTGGGGAGATCAGACCCGAAATCCCATGGTTCCTAC
AGATTCCTGGCTCCATGGATTGGGTACGGCTTGCTCCTGTTGAATGGGCAGACATGGTTC
CAGCATCGACGGATGCTGACCCCAGCCTTCCACTATGACATCCTGAAGCCCTATGTGGGG
CTCATGGCAGACTCTGTACGAGTGATGCTGGACAAATGGGAAGAGCTCCTTGGCCAGGAT
TCCCCTCTGGAGGTCTTTCAGCACGTCTCCTTGATGACCCTGGACACCATCATGAAGTGT
GCCTTCAGCCATCAGGGCAGCATCCAGGTGGACAGGAATTCTCAGTCCTACATACAGGCC
ATTAGTGACCTGAACAACCTGGTTTTTTCCCGTGTGAGGAATGCCTTTCACCAGAATGAC
ACCATCTACAGCCTGACCTCTGCTGGCCGCTGGACACACCGCGCCTGCCAGCTGGCCCAT
CAGCACACAGACCAAGTGATCCAACTGAGGAAGGCTCAACTACAGAAGGAGGGGGAGCTG
GAGAAGATCAAGAGGAAGAGGCATTTGGATTTTCTGGATATCCTCCTCTTGGCCAAAATG
GAGAATGGGAGCATCTTGTCAGACAAGGACCTCCGTGCTGAGGTGGACACGTTCATGTTT
GAGGGCCACGACACCACAGCCAGTGGGATCTCCTGGATCCTCTATGCTCTGGCCACACAC
CCCAAGCATCAGGAGAGGTGCCGGGAGGAGATCCACAGCCTCCTGGGTGATGGAGCCTCC
ATCACCTGGAACCACCTGGACCAGATGCCCTACACCACCATGTGCATTAAGGAGGCACTG
AGGCTCTACCCACCGGTGCCAGGCATTGGCAGAGAGCTCAGCACTCCCGTCACCTTCCCT
GATGGGCGCTCCTTGCCCAAAGGTATCATGGTCCTCCTCTCCATTTATGGCCTTCACCAC
AACCCAAAAGTGTGGCCCAACCCAGAGGTGTTTGACCCTTTCCGTTTTGCACCGGGTTCT
GCTCAACACAGCCACGCTTTCCTGCCCTTCTCAGGAGGATCAAGGAACTGCATCGGGAAA
CAATTTGCCATGAACGAGCTGAAGGTGGCCACGGCCCTGACCCTGCTCCGCTTTGAGCTG
CTGCCTGATCCCACCAGGATCCCCATCCCCATTGCACGACTTGTGTTGAAATCCAAAAAT
GGAATCCACCTGCGTCTCAGGAGGCTCCCTAACCCTTGTGAAGACAAGGACCAGCTTTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alkane 1-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>leukotriene-B4 20-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene B4 catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-chain fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of icosanoid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pressure natriuresis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal water homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>